Amid an EU over-supply of Pfizer’s Covid-19 vaccine, the drug giant is offering to cut the number of doses by 40% and delay deliveries, writes Andy Bounds and Donato Paolo Mancini for the Financial Times. Pfizer has extended its deal with the EU to 2026 but Pfizer’s "insisting on payment for doses ordered in the contract that will never be manufactured," has alienated some in the EU, added the FT story. Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- JPMorgan biotech/pharma analysts to hold analyst/industry conference call
- Seagen price target raised to $229 from $155 at RBC Capital
- Seagen price target raised to $229 from $141 at SVB Securities
- Seagen price target raised to $229 from $210 at Oppenheimer
- Seagen price target raised to $228 from $145 at Barclays
